Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 3/20 | 0.31 |
| ▸ | PDE1A | P54750 | 3/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327279 | 0.89 | KDM4E (0.35) | KDM4ETYMPPOLA1POLBIMPDH2 | |
| SCHEMBL22327282 | 0.89 | KDM4E (0.35) | KDM4ETYMPPOLA1POLBIMPDH2 | |
| SCHEMBL22327402 | 0.86 | TYMP (0.30) | TYMP | |
| SCHEMBL25754037 | 0.86 | TYMP (0.30) | TYMP | |
| SCHEMBL22327400 | 0.86 | TYMP (0.30) | TYMP | |
| SCHEMBL25754138 | 0.86 | PDE9A (0.31) | — | |
| SCHEMBL22598345 | 0.86 | TYMP (0.47) | TYMPPOLA1POLBIMPDH2NT5E | |
| SCHEMBL26068484 | 0.80 | — | — | |
| SCHEMBL26068421 | 0.80 | — | — | |
| SCHEMBL5960166 | 0.79 | IMPDH2 (0.49) | TYMPIMPDH2NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | KDM4E 4194/4885TYMP 5/4885POLA1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.